Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 9Melanoma 5Glioblastoma 5Uterine Cervical Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Brain Neoplasms 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Astrocytoma 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Urethral Neoplasms 1

Interventions

Trastuzumab 2Octreotide 2Leucovorin 2tipifarnib 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Temozolomide 1Sorafenib 1Salts 1Oxaliplatin 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Fluorouracil 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Capecitabine 1Bevacizumab 1Acetates 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Vipoma × Disulfides × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡